KBC Group
SWTX

KBC Group’s SpringWorks Therapeutics SWTX Stock Holding History

KBC Group’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,634
Closed -$116K – 1807
2025
Q1 		$116K Hold
2,634
– – ﹤0.01% 1396
2024
Q4 		$95K Buy
2,634
+978
+59% +$34.2K ﹤0.01% 1593
2024
Q3 		$53K Hold
1,656
– – ﹤0.01% 1688
2024
Q2 		$62K Buy
1,656
+500
+43% +$21K ﹤0.01% 1491
2024
Q1 		$57K Buy
+1,156
New +$53.4K ﹤0.01% 1475

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

KBC Group's SWTX Position: Q2 2025 in Review

KBC Group sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 2,634 shares — an estimated $116K sold.

KBC Group first reported a position in SWTX in Q1 2024 and held it in 5 quarters. The position peaked at $116K in Q1 2025. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • KBC Group reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • KBC Group sold 2,634 SpringWorks Therapeutics shares in Q2 2025, an estimated $116K.
  • KBC Group first reported a position in SpringWorks Therapeutics in Q1 2024 and held it in 5 quarters.
  • KBC Group's SpringWorks Therapeutics position peaked at $116K in Q1 2025.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on KBC Group's 13F filing for Q2 2025, filed 8 Aug 2025.